These studies collectively highlight the potential of CRISPR-mediated gene editing to directly target and mitigate the molecular pathology of ALS caused by SOD1 mutations and C9orf72 repeat expansions. This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.